Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
- PMID: 31836685
- PMCID: PMC7413240
- DOI: 10.2967/jnumed.119.236786
Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
Abstract
Targeting cancer-associated fibroblasts (CAFs) has become an attractive goal for diagnostic imaging and therapy because they can constitute as much as 90% of a tumor mass. The serine protease fibroblast activation protein (FAP) is overexpressed selectively in CAFs, drawing interest in FAP as a stromal target. The quinoline-based FAP inhibitor (FAPI) PET tracer 68Ga-FAPI-04 has been previously shown to yield high tumor-to-background ratios (TBRs) in patients with various cancers. Recent developments toward an improved compound for therapeutic application have identified FAPI-46 as a promising agent because of an increased tumor retention time in comparison with FAPI-04. Here, we present a PET biodistribution and radiation dosimetry study of 68Ga-FAPI-46 in cancer patients. Methods: Six patients with different cancers underwent serial 68Ga-FAPI-46 PET/CT scans at 3 time points after radiotracer injection: 10 min, 1 h, and 3 h. The source organs consisted of the kidneys, bladder, liver, heart, spleen, bone marrow, uterus, and remainder of body. OLINDA/EXM software, version 1.1, was used to fit and integrate the kinetic organ activity data to yield total-body and organ time-integrated activity coefficients and residence times and, finally, organ-absorbed doses. SUVs and TBR were generated from the contoured tumor and source-organ volumes. Spheric volumes in muscle and blood pool were also obtained for TBR (tumor SUVmax/organ SUVmean). Results: At all time points, average SUVmax was highest in the liver. Tumor and organ SUVmean decreased over time, whereas TBRs in all organs but the uterus increased. The organs with the highest effective doses were bladder wall (2.41E-03 mSv/MBq), followed by ovaries (1.15E-03 mSv/MBq) and red marrow (8.49E-04 mSv/MBq). The average effective total-body dose was 7.80E-03 mSv/MBq. Conclusion:68Ga-FAPI-46 PET/CT has a favorable dosimetry profile, with an estimated whole-body dose of 5.3 mSv for an administration of 200 MBq (5.4 mCi) of 68Ga-FAPI-46 (1.56 ± 0.26 mSv from the PET tracer and 3.7 mSv from 1 low-dose CT scan). The biodistribution study showed high TBRs increasing over time, suggesting high diagnostic performance and favorable tracer kinetics for potential therapeutic applications.
Keywords: 68Ga; FAPI; PET/CT; biodistribution; dosimetry.
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.
Figures
Similar articles
-
68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers.J Nucl Med. 2019 Mar;60(3):386-392. doi: 10.2967/jnumed.118.215913. Epub 2018 Aug 2. J Nucl Med. 2019. PMID: 30072500 Free PMC article.
-
Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers.Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1915-1931. doi: 10.1007/s00259-020-05132-y. Epub 2020 Nov 26. Eur J Nucl Med Mol Imaging. 2021. PMID: 33244617
-
68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG.J Nucl Med. 2024 Jun 3;65(6):938-943. doi: 10.2967/jnumed.123.267281. J Nucl Med. 2024. PMID: 38697672
-
Performance and Prospects of [68Ga]Ga-FAPI PET/CT Scans in Lung Cancer.Cancers (Basel). 2022 Nov 13;14(22):5566. doi: 10.3390/cancers14225566. Cancers (Basel). 2022. PMID: 36428657 Free PMC article. Review.
-
Non-oncologic incidental uptake on FAPI PET/CT imaging.Br J Radiol. 2023 Feb;96(1142):20220463. doi: 10.1259/bjr.20220463. Epub 2022 Jul 13. Br J Radiol. 2023. PMID: 35776566 Free PMC article. Review.
Cited by
-
Generic semi-automated radiofluorination strategy for single domain antibodies: [18F]FB-labelled single domain antibodies for PET imaging of fibroblast activation protein-α or folate receptor-α overexpression in cancer.EJNMMI Radiopharm Chem. 2024 Jul 24;9(1):54. doi: 10.1186/s41181-024-00286-8. EJNMMI Radiopharm Chem. 2024. PMID: 39048805 Free PMC article.
-
Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2.Molecules. 2024 Jun 28;29(13):3093. doi: 10.3390/molecules29133093. Molecules. 2024. PMID: 38999044 Free PMC article.
-
Diagnostic accuracy and clinical value of [68Ga]Ga-FAPI-46 PET/CT for staging patients with ovarian cancer: study protocol for a prospective clinical trial.BMC Cancer. 2024 Jun 7;24(1):699. doi: 10.1186/s12885-024-12461-w. BMC Cancer. 2024. PMID: 38849741 Free PMC article.
-
Non-specific uptake of 18F-FAPI-04 in the pancreas and its related factors: a post-hoc analysis of an ongoing prospective clinical trial.Sci Rep. 2024 May 15;14(1):11141. doi: 10.1038/s41598-024-62005-2. Sci Rep. 2024. PMID: 38750103 Free PMC article. Clinical Trial.
-
Development and Characterization of Novel FAP-Targeted Theranostic Pairs: A Bench-to-Bedside Study.Research (Wash D C). 2023 Nov 28;6:0282. doi: 10.34133/research.0282. eCollection 2023. Research (Wash D C). 2023. PMID: 38706713 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous